Argá Medtech Secures €54M in Series B Funding
March 4, 2024, 8:30 pm
Location: Switzerland, Vaud, Epalinges
Employees: 11-50
Founded date: 2020
Total raised: $58.57M
Argá Medtech, a Swiss company specializing in cardiac ablation systems, recently closed a successful €54 million Series B funding round. The funding was oversubscribed, demonstrating strong investor interest in the company's innovative technology.
Existing investors Advent Life Sciences and Earlybird Health, along with new investors Gilde Healthcare and an undisclosed investor, led the funding round. This financial support will enable Argá Medtech to further develop its CSE™ Pulsed Field Ablation (PFA) system for treating atrial fibrillation (AF) through clinical studies in the US and EU.
CEO David Neale expressed excitement about the funding, stating that it will help the company validate its technology and bring a safe, fast, and effective treatment to millions of people suffering from cardiac rhythm disorders. Argá Medtech's unique catheter design and CSE™ PFA waveform allow for precise energy delivery, resulting in durable lesions for patients with cardiac arrhythmias.
The company has already conducted a successful first-in-human study in Europe, showcasing the high performance of its platform in treating AF. With plans to expand its US presence in San Diego, CA, Argá Medtech is poised to advance its clinical activities and make a significant impact in the field of cardiac ablation.
Overall, the successful Series B funding round positions Argá Medtech as a key player in the development of innovative solutions for cardiac arrhythmias, offering hope to patients worldwide.
Existing investors Advent Life Sciences and Earlybird Health, along with new investors Gilde Healthcare and an undisclosed investor, led the funding round. This financial support will enable Argá Medtech to further develop its CSE™ Pulsed Field Ablation (PFA) system for treating atrial fibrillation (AF) through clinical studies in the US and EU.
CEO David Neale expressed excitement about the funding, stating that it will help the company validate its technology and bring a safe, fast, and effective treatment to millions of people suffering from cardiac rhythm disorders. Argá Medtech's unique catheter design and CSE™ PFA waveform allow for precise energy delivery, resulting in durable lesions for patients with cardiac arrhythmias.
The company has already conducted a successful first-in-human study in Europe, showcasing the high performance of its platform in treating AF. With plans to expand its US presence in San Diego, CA, Argá Medtech is poised to advance its clinical activities and make a significant impact in the field of cardiac ablation.
Overall, the successful Series B funding round positions Argá Medtech as a key player in the development of innovative solutions for cardiac arrhythmias, offering hope to patients worldwide.